Erythropoietin: Powerful protection of ischemic and post-ischemic brain

Abstract

Ischemic brain injury inflicted by stroke and cardiac arrest ranks among the leading causes of death and long-term disability in the United States. The brain consumes large amounts of metabolic substrates and oxygen to sustain its energy requirements. Consequently, the brain is exquisitely sensitive to interruptions in its blood supply, and suffers irreversible damage after 10–15 minutes of severe ischemia. Effective treatments to protect the brain from stroke and cardiac arrest have proven elusive, due to the complexities of the injury cascades ignited by ischemia and reperfusion. Although recombinant tissue plasminogen activator and therapeutic hypothermia have proven efficacious for stroke and cardiac arrest, respectively, these treatments are constrained by narrow therapeutic windows, potentially detrimental side effects and the limited availability of hypothermia equipment. Mounting evidence demonstrates the cytokine hormone erythropoietin (EPO) to be a powerful neuroprotective agent and a potential adjuvant to established therapies. Classically, EPO originating primarily in the kidneys promotes erythrocyte production by suppressing apoptosis of proerythroid progenitors in bone marrow. However, the brain is capable of producing EPO, and EPO’s membrane receptors and signaling components also are expressed in neurons and astrocytes. EPO activates signaling cascades that increase the brain’s resistance to ischemia-reperfusion stress by stabilizing mitochondrial membranes, limiting formation of reactive oxygen and nitrogen intermediates, and suppressing pro-inflammatory cytokine production and neutrophil infiltration. Collectively, these mechanisms preserve functional brain tissue and, thus, improve neurocognitive recovery from brain ischemia. This article reviews the mechanisms mediating EPO-induced brain protection, critiques the clinical utility of exogenous EPO to preserve brain threatened by ischemic stroke and cardiac arrest, and discusses the prospects for induction of EPO production within the brain by the intermediary metabolite, pyruvate.

Intermittent hypoxia training protects cerebrovascular function in Alzheimer's disease

“…For example, HIF-1-driven expression of glycolytic enzymes 122 could increase O 2 -independent ATP production, and erythropoietin, long recognized for its pivotal role in hematopoiesis, 123 also can be synthesized within the brain, where it exerts a host of neuroprotective actions. 124 IHT improves endothelial production of NO Normally, NO involved in cerebral blood flow regulation is produced by endothelial cells, neurons, and nitrergic perivascular nerves. 125 In addition to regulating cerebral blood flow, endothelial NO is vaso-and neuroprotective due to its antiplatelet, antithrombotic, antiproliferative, and antiatherosclerotic functions.…”

Featured Article: Pyruvate preserves antiglycation defenses in porcine brain after cardiac arrest

“…Cardiocerebral resuscitation (CCR) and effective cardiac defibrillation reperfuse the ischemic brain, but reperfusion ignites an explosive burst of reactive oxygen, nitrogen and dicarbonyl formation which intensifies intracellular Ca 2þ overload, glutamate excitotoxicity and inflammation, culminating in extensive neuronal death. 2 However, numerous clinical trials failed to demonstrate appreciable neurocognitive benefits of antioxidant and antiinflammatory interventions after CA and CCR. 3,4 The powerful glycating dicarbonyl methylglyoxal, a product of spontaneous decomposition of the glycolytic intermediates glyceraldehyde 3-phosphate (GAP) and dihydroxyacetone phosphate (DHAP), has been implicated in the pathogenesis of Alzheimer's Disease, Parkinson's Disease, and other neurodegenerative disorders.…”

Chronic Treatment With an Erythropoietin Receptor Ligand Prevents Chronic Kidney Disease–Induced Enlargement of Myocardial Infarct Size

“…10 Erythropoietin receptors are also expressed not only in hematopoietic cells but also in other types of cells, such as endothelial cells, neurons, and cardiomyocytes. [11][12][13] A series of studies using a mutant mouse that expresses the erythropoietin receptor exclusively in hematopoietic cells (EpoR −/− rescued) showed that deletion of the erythropoietin receptor aggravates I/R injury and Abstract-Chronic kidney disease (CKD) is known to increase myocardial infarct size after ischemia/reperfusion. However, a strategy to prevent the CKD-induced myocardial susceptibility to ischemia/reperfusion injury has not been developed.…”